Literature DB >> 36050467

GPNMB: a potent inducer of immunosuppression in cancer.

Anna-Maria Lazaratos1, Matthew G Annis1,2, Peter M Siegel3,4,5,6,7.   

Abstract

The immune system is comprised of both innate and adaptive immune cells, which, in the context of cancer, collectively function to eliminate tumor cells. However, tumors can actively sculpt the immune landscape to favor the establishment of an immunosuppressive microenvironment, which promotes tumor growth and progression to metastatic disease. Glycoprotein-NMB (GPNMB) is a transmembrane glycoprotein that is overexpressed in a variety of cancers. It can promote primary tumor growth and metastasis, and GPNMB expression correlates with poor prognosis and shorter recurrence-free survival in patients. There is growing evidence supporting an immunosuppressive role for GPNMB in the context of malignancy. This review provides a description of the emerging roles of GPNMB as an inducer of immunosuppression, with a particular focus on its role in mediating cancer progression by restraining pro-inflammatory innate and adaptive immune responses.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36050467     DOI: 10.1038/s41388-022-02443-2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  93 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 3.  Gpnmb/osteoactivin: an indicator and therapeutic target in tumor and nontumorous lesions.

Authors:  Hui Zhuo; Letian Zhou
Journal:  Pharmazie       Date:  2016-10-01       Impact factor: 1.267

Review 4.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

5.  ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.

Authors:  April A N Rose; Matthew G Annis; Zhifeng Dong; Francois Pepin; Michael Hallett; Morag Park; Peter M Siegel
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 6.  Cancer immunoediting and resistance to T cell-based immunotherapy.

Authors:  Michele W L Teng; Mark J Smyth; Jake S O'Donnell
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

Review 7.  Therapeutic Targeting of the Tumor Microenvironment.

Authors:  Leire Bejarano; Marta J C Jordāo; Johanna A Joyce
Journal:  Cancer Discov       Date:  2021-04       Impact factor: 39.397

Review 8.  Targeting metastatic cancer.

Authors:  Karuna Ganesh; Joan Massagué
Journal:  Nat Med       Date:  2021-01-13       Impact factor: 53.440

9.  Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.

Authors:  Gordana Maric; April An Rose; Matthew G Annis; Peter M Siegel
Journal:  Onco Targets Ther       Date:  2013-07-09       Impact factor: 4.147

10.  GPNMB is expressed in human epidermal keratinocytes but disappears in the vitiligo lesional skin.

Authors:  Kazal Boron Biswas; Aya Takahashi; Yukiko Mizutani; Satoru Takayama; Asako Ishitsuka; Lingli Yang; Fei Yang; Arunasiri Iddamalgoda; Ichiro Katayama; Shintaro Inoue
Journal:  Sci Rep       Date:  2020-03-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.